Bedfont® Scientific strengthens its commitment to respiratory clinical research

Bedfont^® Scientific Limited, a world leader in breath analysis with 50 years of experience manufacturing medical devices, has quietly supported respiratory research around the world and is set to make its debut at its first clinical trial-focused event in November, taking the next step toward a dedicated focus on supporting clinical trials and clinical research teams, marking the beginning of a new chapter at Bedfont^®.

Outsourcing in Clinical Trials (OCT) DACH is an annual conference that brings together professionals involved in the planning, management and outsourcing of clinical trials across Germany, Austria and Switzerland. As Bedfont^® expands its focus on supporting clinical trials, attending OCT DACH is the perfect opportunity to engage directly with the professionals shaping the future of clinical research.

The future of respiratory medicine depends on robust clinical research. As biomarkers continue to play an increasingly important role in clinical trials, researchers need partners they can rely on for both scientific expertise and dependable technology. Building on our experience in respiratory diagnostics and the established use of NObreath^® in clinical studies, we are excited to strengthen our support for the clinical research community and look forward to building relationships with the organizations leading respiratory studies at OCT DACH in November."

Jason Smith, CEO, Bedfont^®

The NObreath^® FeNO device has been aiding asthma diagnosis and management for over 15 years. Designed for reliability, NObreath^® provides accurate, repeatable FeNO measurements for long-term studies, making it the perfect choice for clinical trials. You can find the Bedfont^® team at stand 10b for live demonstrations of NObreath^® and to see how straightforward it is to incorporate FeNO testing into clinical trial protocols and patient visits.